6533b7d8fe1ef96bd126b008

RESEARCH PRODUCT

Drug‐refractory myasthenia gravis: Clinical characteristics, treatments, and outcome

Elena Cortés‐vicenteRodrigo ÁLvarez‐velascoFrancesc Pla‐juncaRicard Rojas‐garciaCarmen ParadasTeresa SevillaCarlos CasasnovasMaría Teresa Gómez‐caravacaJulio PardoAlba Ramos‐fransiAna Lara Pelayo‐negroGerardo Gutiérrez-gutiérrezJanina Turon‐sansAdolfo López De MunainAntonio Guerrero‐solaIvonne JericóMaría Asunción MartínMaría Dolores MendozaGermán MorísBeatriz Vélez-gómezTania Garcia‐sobrinoElba Pascual‐goñiDavid Reyes‐leivaIsabel IllaEduard Gallardo

subject

Maleprogressive multifocal leukoencepdiarrheacholinergic receptorplasma exchangemiddle agedadultimmunologic factornauseaanemiahypertrichosisageddrug withdrawaldiabetes mellitusdisease severityTRIALsafetycorticosteroidhypertensionImmunologyMiastenia gravismethotrexateArticlebulbar paralysispancytopeniaMuscular DiseasescompulsionMyasthenia Gravischolinesterase inhibitorcross-sectional studyHumansImmunologic FactorshumanRITUXIMABarthralgiaNeurologíaMalalties muscularsAgedRetrospective Studiesmyasthenia gravisleukopeniaabdominal painDrug testingmajor clinical studyCross-Sectional StudiesDrug side effectscyclophosphamideobservational studyNeurology (clinical)immunoglobulinFEATURESefficacyclinical outcomeelectrophysiological procedurescomputer assisted tomographyDOUBLE-BLINDTratamiento médicorituximabOutcome Assessment Health CareImmunologiamuscle specific tyrosine kinaseRegistriestacrolimusazathioprineMedicamentoGeneral Neurosciencenephrotoxicitygeneral condition deteriorationhyperplasiatrialMiddle Agedliver toxicitydrug toxicityunclassified drugfemaleEfectes secundaris dels medicamentsSAFETYFemaledouble-blindheadacheblindnessAdultAssaigs clínics de medicamentsmalefeaturesfollow uppneumoniacyclosporinemycophenolate mofetilprotein tyrosine kinaseimmunosuppressive agentallergyalopeciaEFFICACYclinical featureosteopeniaSpainprednisonehyperglycemiaautoantibodyFollow-Up Studies

description

[Objective] To describe the clinical characteristics and outcomes in patients with refractory myasthenia gravis (MG) and to determine the effectiveness and side effects of the drugs used for their treatment.

10.1002/acn3.51492https://hdl.handle.net/11268/11525